ES002023

anti-CD39 antibody · Elpiscience Biopharma, Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ES002023, covering 2025-05-14 to 2025-05-14. Get the full timeline:

Most recent: Clinical Trial Update: A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors [Phase 1]